Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.

Front Pharmacol · 2020 · PMC7769953 · PMID 33384605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an evident trendno p-value reported

By contrast, in patients with critical disease, the beneficial effect of anti-IL-6/IL-6R/JAK antibodies on mortality became indistinct, and resulted in an evident trend of increased secondary infection rates.

also in 268 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.